IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

IGH::FENDRR and KRAS mutations define a novel B-ALL subtype with 85% poor chemotherapy response.

• Why it matters: Identifying new molecular subtypes of B-ALL is crucial for improving treatment strategies, especially for cases resistant to standard chemotherapy.
• What they did: Analyzing 4857 patients across three cohorts, researchers discovered a distinct subgroup characterized by IGH::FENDRR rearrangement, KRAS p.A146T/V/P mutations, and unique gene expression profiles, including FOXF1/FENDRR overexpression.
• The result: This subtype exhibits very poor initial treatment response but shows potential for remission with intensified therapies like blinatumomab or stem cell transplantation, highlighting the need for targeted early interventions.